Merck Recalls PedvaxHIB Vaccine, Sanofi Steps Up Production To Fill Void
Executive Summary
Merck's voluntary recall of its PedvaxHIB vaccine is causing a short-term shortage of Haemophilus influenza type b vaccine supply in the U.S
You may also be interested in...
GSK's Hiberix Vaccine Approved, But Is Catch-Up A Sustainable Strategy?
FDA grants accelerated approval to GSK's Hib product after a prolonged shortage of Merck's vaccine.
As Sales Slip, Merck & Co. Plans 7,200 Job Cuts
Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.
Merck Faces Varicella-Zoster Virus Supply Shortage For Vaccine Production
Merck does not expect problems in the production of bulk varicella-zoster virus vaccine to affect near-term supplies of individual products that contain the virus - the varicella vaccine Varivax, the herpes zoster vaccine Zostavax, and the measles, mumps, rubella and varicella (MMR-V) combination ProQuad